Yu, Ming-Lung <br/><br/>
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.  [electronic resource] 

 -  Journal of the Formosan Medical Association = Taiwan yi zhi  Feb 2019 
 - 556-564 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0929-6646 
<br/><br/><label>Standard No.: </label>10.1016/j.jfma.2018.11.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antiviral Agents--administration & dosage<br/>Carbamates<br/>Drug Resistance, Viral--genetics<br/>Drug Therapy, Combination<br/>Female<br/>Hepacivirus<br/>Hepatitis C, Chronic--drug therapy<br/>Humans<br/>Imidazoles--administration & dosage<br/>Isoquinolines--administration & dosage<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Pyrrolidines<br/>RNA, Viral--blood<br/>Ribavirin--administration & dosage<br/>Sulfonamides--administration & dosage<br/>Sustained Virologic Response<br/>Taiwan<br/>Valine--analogs & derivatives<br/>Viral Nonstructural Proteins--genetics